Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axonyx continues phenserine evaluation

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Axonyx believes a subgroup analysis of failed Phase III trials for its Alzheimer's therapy phenserine supports its position that higher doses of the treatment "could potentially be efficacious in treating the signs and symptoms of mild to moderate AD in future potential Phase III trials," the firm says Nov. 29. In a subgroup of patients receiving phenserine 15 mg twice daily, a statistically significant benefit over placebo was seen in the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog). "This additional analysis was recently completed as part of the program to identify a partner for the further development of phenserine," Axonyx says. Axonyx initially announced disappointing results for phenserine in February, then again in September (Pharmaceutical Approvals Monthly October 2005, In Brief)...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS003134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel